DK2808393T3 - Celler, der er utilstrækkelige til fucosylering - Google Patents

Celler, der er utilstrækkelige til fucosylering Download PDF

Info

Publication number
DK2808393T3
DK2808393T3 DK14179885.0T DK14179885T DK2808393T3 DK 2808393 T3 DK2808393 T3 DK 2808393T3 DK 14179885 T DK14179885 T DK 14179885T DK 2808393 T3 DK2808393 T3 DK 2808393T3
Authority
DK
Denmark
Prior art keywords
cell
cells
fucosylation
fucose
val
Prior art date
Application number
DK14179885.0T
Other languages
English (en)
Inventor
Gang Chen
Darya Burakov
James P Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK2808393T3 publication Critical patent/DK2808393T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (7)

1. En celle, som udtrykker et GDP-4-keto-6-deoxy-mannose-3,5-epimerase-4-reduktase (FX)-protein med en modifikation, hvor FX-proteinmodifikationen omfatter aminosyreerstatningen 289S og mindst en yderligere modifikation, der er udvalgt fra en gruppe bestående af følgende aminosyresubstitutioner: 90K, 211R, 136L og 79S, hvor cellen også udtrykker et glykoprotein, og hvor FX-proteinmodifikationen mindst resulterer i en 90 %-reduktion i cellens evne til at fucosylere glykoproteinet sammenlignet med en celle, som mangler modifikationen.
2. Cellen i krav 1, hvor modifikationen omfatter aminosyresubstitutionerne 289S og 90K.
3. Cellen i et hvilket som helst af kravene 1-2, hvor cellen er en CHO-celle.
4. Cellen i et hvilket som helst af kravene 1-3, hvor FX-proteinet er mindst 90 % identisk eller mindst 95 % identisk med SEQ ID NR: 1.
5. Cellen i et hvilket som helst af kravene 1-4, hvor glykoproteinet er et antistof.
6. En metode til fremstilling af et antigen-bindende protein, idet metoden omfatter: (a) fremskaffelse af cellen i et hvilket som helst af kravene 1 til 5, (b) indføring af en nukleinsyresekvens i cellen, som koder et antigen-bindende protein; (c) fastholdelse af cellen under forhold, som er tilstrækkelige til at udtrykke nukleinsyresekvensen for at producere det antigen-bindende protein; og (d) genvinding af det antigen-bindende protein udtrykt af cellen.
7. Metoden i krav 6, hvor det antigen-bindende protein er et antistof.
DK14179885.0T 2009-06-02 2010-06-01 Celler, der er utilstrækkelige til fucosylering DK2808393T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US34885810P 2010-05-27 2010-05-27
EP10721096.5A EP2438171B1 (en) 2009-06-02 2010-06-01 Fucosylation-deficient cells

Publications (1)

Publication Number Publication Date
DK2808393T3 true DK2808393T3 (da) 2018-03-12

Family

ID=42338231

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17192430.1T DK3279326T3 (da) 2009-06-02 2010-06-01 Fucosyleringsdeficiente celler
DK14179885.0T DK2808393T3 (da) 2009-06-02 2010-06-01 Celler, der er utilstrækkelige til fucosylering
DK10721096.5T DK2438171T3 (da) 2009-06-02 2010-06-01 Fucosylerings-deficiente celler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17192430.1T DK3279326T3 (da) 2009-06-02 2010-06-01 Fucosyleringsdeficiente celler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10721096.5T DK2438171T3 (da) 2009-06-02 2010-06-01 Fucosylerings-deficiente celler

Country Status (17)

Country Link
US (8) US8409838B2 (da)
EP (3) EP2438171B1 (da)
JP (4) JP5744856B2 (da)
KR (2) KR101641526B1 (da)
CN (1) CN102459603B (da)
AU (1) AU2010256753B2 (da)
BR (1) BRPI1010035A2 (da)
CA (1) CA2764370C (da)
DK (3) DK3279326T3 (da)
ES (2) ES2661074T3 (da)
HK (3) HK1198180A1 (da)
HU (1) HUE038596T2 (da)
IL (1) IL216624A (da)
PL (3) PL2438171T3 (da)
SG (1) SG176251A1 (da)
TW (1) TWI513818B (da)
WO (1) WO2010141478A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
HUE038596T2 (hu) 2009-06-02 2018-10-29 Regeneron Pharma Fukoziláció-hiányos sejtek
CN103597073B (zh) 2011-03-06 2019-06-07 默克雪兰诺有限公司 低岩藻糖细胞系及其应用
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
US20150093782A1 (en) * 2013-10-01 2015-04-02 The University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
EP3149034B1 (en) * 2014-05-30 2022-07-13 New England Biolabs, Inc. Deglycosylation reagents and methods
SG11201610699XA (en) * 2014-07-07 2017-01-27 Targazyme Inc Manufacture and cryopreservation of fucosylated cells for therapeutic use
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3925970A1 (en) 2015-11-02 2021-12-22 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein
US20190161543A1 (en) 2016-01-06 2019-05-30 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
CA3015389A1 (en) * 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
KR20180134894A (ko) 2016-04-20 2018-12-19 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
WO2020042015A1 (en) * 2018-08-29 2020-03-05 United Biopharma Inc Afucosylated antibodies and manufacture thereof
US20220002389A1 (en) 2018-10-29 2022-01-06 Immuno-Biological Laboratories Co., Ltd. Anti-hiv antibody and method for producing same
AU2021282179A1 (en) 2020-05-26 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
CN116057069A (zh) 2020-06-03 2023-05-02 瑞泽恩制药公司 用抗SARS-CoV-2刺突糖蛋白抗体治疗或预防SARS-CoV-2感染和COVID-19的方法
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
KR20240024061A (ko) 2021-06-22 2024-02-23 리제너론 파마슈티칼스 인코포레이티드 항-EGFRvIII 항체 약물 접합체 및 이의 용도
CA3225575A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
WO2023167871A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006070A (en) 1909-05-11 1911-10-17 George Walter Durbrow Method of and means for extracting micro-organisms and solids from water.
EP2275541B1 (en) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のｇｄｐ−４−ケト−６−デオキシ−ｄ−マンノース−３，５−エピメラーゼ−４−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006133148A2 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
CA2679732A1 (en) 2007-03-07 2008-09-18 Glycofi, Inc. Production of glycoproteins with modified fucosylation
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
EP2311864A4 (en) 2008-08-13 2013-07-31 Kyowa Hakko Kirin Co Ltd RECOMBINANT PROTEIN-S COMPOSITION
HUE038596T2 (hu) 2009-06-02 2018-10-29 Regeneron Pharma Fukoziláció-hiányos sejtek
CN103597073B (zh) 2011-03-06 2019-06-07 默克雪兰诺有限公司 低岩藻糖细胞系及其应用

Also Published As

Publication number Publication date
ES2527173T3 (es) 2015-01-21
CN102459603B (zh) 2013-11-06
EP2808393A3 (en) 2015-03-11
EP2438171A1 (en) 2012-04-11
EP2808393B1 (en) 2018-01-10
WO2010141478A1 (en) 2010-12-09
US20210254022A1 (en) 2021-08-19
JP5744856B2 (ja) 2015-07-08
US9206455B2 (en) 2015-12-08
JP2015051021A (ja) 2015-03-19
JP2016104045A (ja) 2016-06-09
BRPI1010035A2 (pt) 2015-08-25
KR20140039340A (ko) 2014-04-01
DK2438171T3 (da) 2015-01-26
HK1249547A1 (zh) 2018-11-02
EP2438171B1 (en) 2014-12-17
PL2438171T3 (pl) 2015-04-30
KR20120029443A (ko) 2012-03-26
US11560550B2 (en) 2023-01-24
SG176251A1 (en) 2011-12-29
US20160090410A1 (en) 2016-03-31
US8409838B2 (en) 2013-04-02
CA2764370A1 (en) 2010-12-09
IL216624A0 (en) 2012-02-29
PL2808393T3 (pl) 2018-04-30
EP3279326B1 (en) 2020-10-14
HK1198180A1 (en) 2015-03-13
KR101641526B1 (ko) 2016-07-21
HUE038596T2 (hu) 2018-10-29
TW201107469A (en) 2011-03-01
US20190024129A1 (en) 2019-01-24
US20100304436A1 (en) 2010-12-02
AU2010256753A1 (en) 2012-01-12
CN102459603A (zh) 2012-05-16
PL3279326T3 (pl) 2021-03-08
HK1163745A1 (en) 2012-09-14
EP2808393A2 (en) 2014-12-03
US12054751B2 (en) 2024-08-06
DK3279326T3 (da) 2020-12-21
JP2017006147A (ja) 2017-01-12
US10006070B2 (en) 2018-06-26
KR101441437B1 (ko) 2014-09-25
TWI513818B (zh) 2015-12-21
EP3279326A1 (en) 2018-02-07
US20170211115A1 (en) 2017-07-27
CA2764370C (en) 2018-08-21
US20200080124A1 (en) 2020-03-12
ES2661074T3 (es) 2018-03-27
US20130164786A1 (en) 2013-06-27
US9550823B2 (en) 2017-01-24
IL216624A (en) 2015-02-26
JP6211642B2 (ja) 2017-10-11
US20230295583A1 (en) 2023-09-21
AU2010256753B2 (en) 2013-11-28
JP2012528594A (ja) 2012-11-15

Similar Documents

Publication Publication Date Title
US11560550B2 (en) Fucosylation-deficient cells
AU2015282354B2 (en) Fucosylation-deficient cells
AU2014200152B2 (en) Fucosylation-deficient cells
AU2012100020A6 (en) Fucosylation-deficient cells
ES2834048T3 (es) Células deficientes en fucosilación